CSNpharm

CSNpharm logo

Csnpharm is committed to providing you with high quality products and outstanding services. We supply over 5000 bioactive compounds in stock, including inhibitors, agonists and natural products for laboratory and scientific use. Csnpharm has always been committed to develop quality products that are validated by NMR, UPLC, LC-MS, GC, Chiral HPLC and so on. We have a professional technical support team for customer service with years of experience in life science. Csnpharm is your reliable partner for scientific research.

Company Website

Product Listing

EIDD-1931 100mg  | ≥99%

CSNpharm

EIDD-1931 has a broad-spectrum antiviral activity against multiple coronaviruses, including SARS-CoV2, MERS-CoV, SARS-CoV. and related zoonotic group 2b or 2c Bat-CoVs, as well as increased potency against a coronavirus bearing resistance mutations to another nucleoside analog inhibitor.

More Information Supplier Page

EIDD-1931 50mg  | ≥99%

CSNpharm

EIDD-1931 has a broad-spectrum antiviral activity against multiple coronaviruses, including SARS-CoV2, MERS-CoV, SARS-CoV. and related zoonotic group 2b or 2c Bat-CoVs, as well as increased potency against a coronavirus bearing resistance mutations to another nucleoside analog inhibitor.

More Information Supplier Page

EIDD-1931 25mg  | ≥99%

CSNpharm

EIDD-1931 has a broad-spectrum antiviral activity against multiple coronaviruses, including SARS-CoV2, MERS-CoV, SARS-CoV. and related zoonotic group 2b or 2c Bat-CoVs, as well as increased potency against a coronavirus bearing resistance mutations to another nucleoside analog inhibitor.

More Information Supplier Page

EIPA 5mg  | ≥98%

CSNpharm

EIPA (L593754) is a TRPP3 channel inhibitor with an IC50 of 10.5 μM. EIPA also inhibits Na+/H+-exchanger (NHE) and macropinocytosis[1][2][3].

More Information Supplier Page

EIPA 10mg  | ≥98%

CSNpharm

EIPA (L593754) is a TRPP3 channel inhibitor with an IC50 of 10.5 μM. EIPA also inhibits Na+/H+-exchanger (NHE) and macropinocytosis[1][2][3].

More Information Supplier Page

Elacridar 250mg  | ≥99%

CSNpharm

Elacridar is a P-glycoprotein inhibitor, and has been used both in vitro and in vivo as a tool inhibitor of P-glycoprotein (Pgp) to investigate the role of transporters in the disposition of various test molecules.

More Information Supplier Page

Elacridar 25mg  | ≥99%

CSNpharm

Elacridar is a P-glycoprotein inhibitor, and has been used both in vitro and in vivo as a tool inhibitor of P-glycoprotein (Pgp) to investigate the role of transporters in the disposition of various test molecules.

More Information Supplier Page

Elacridar 100mg  | ≥99%

CSNpharm

Elacridar is a P-glycoprotein inhibitor, and has been used both in vitro and in vivo as a tool inhibitor of P-glycoprotein (Pgp) to investigate the role of transporters in the disposition of various test molecules.

More Information Supplier Page

Elacridar 5mg  | ≥99%

CSNpharm

Elacridar is a P-glycoprotein inhibitor, and has been used both in vitro and in vivo as a tool inhibitor of P-glycoprotein (Pgp) to investigate the role of transporters in the disposition of various test molecules.

More Information Supplier Page

Elacridar 50mg  | ≥99%

CSNpharm

Elacridar is a P-glycoprotein inhibitor, and has been used both in vitro and in vivo as a tool inhibitor of P-glycoprotein (Pgp) to investigate the role of transporters in the disposition of various test molecules.

More Information Supplier Page

Elacridar 10mg  | ≥99%

CSNpharm

Elacridar is a P-glycoprotein inhibitor, and has been used both in vitro and in vivo as a tool inhibitor of P-glycoprotein (Pgp) to investigate the role of transporters in the disposition of various test molecules.

More Information Supplier Page

Elbasvir 1mg  | ≥99%

CSNpharm

Elbasvir is an inhibitor of nonstructural protein 5A (NS5A) of hepatitis C virus (HCV). It can be used to treat chronic HCV infection.

More Information Supplier Page

Elbasvir 10mg  | ≥99%

CSNpharm

Elbasvir is an inhibitor of nonstructural protein 5A (NS5A) of hepatitis C virus (HCV). It can be used to treat chronic HCV infection.

More Information Supplier Page

Elbasvir 25mg  | ≥99%

CSNpharm

Elbasvir is an inhibitor of nonstructural protein 5A (NS5A) of hepatitis C virus (HCV). It can be used to treat chronic HCV infection.

More Information Supplier Page

Elbasvir 50mg  | ≥99%

CSNpharm

Elbasvir is an inhibitor of nonstructural protein 5A (NS5A) of hepatitis C virus (HCV). It can be used to treat chronic HCV infection.

More Information Supplier Page

Elbasvir 2mg  | ≥99%

CSNpharm

Elbasvir is an inhibitor of nonstructural protein 5A (NS5A) of hepatitis C virus (HCV). It can be used to treat chronic HCV infection.

More Information Supplier Page

Elbasvir 5mg  | ≥99%

CSNpharm

Elbasvir is an inhibitor of nonstructural protein 5A (NS5A) of hepatitis C virus (HCV). It can be used to treat chronic HCV infection.

More Information Supplier Page

Eleutheroside E 25mg  | ≥98%

CSNpharm

Eleutheroside E, a principal component of Eleutherococcus enticosus, has anti-inflammatory and protective effects in ischemia heart.

More Information Supplier Page

Eleutheroside E 5mg  | ≥98%

CSNpharm

Eleutheroside E, a principal component of Eleutherococcus enticosus, has anti-inflammatory and protective effects in ischemia heart.

More Information Supplier Page

Eleutheroside E 100mg  | ≥98%

CSNpharm

Eleutheroside E, a principal component of Eleutherococcus enticosus, has anti-inflammatory and protective effects in ischemia heart.

More Information Supplier Page

Eleutheroside E 50mg  | ≥98%

CSNpharm

Eleutheroside E, a principal component of Eleutherococcus enticosus, has anti-inflammatory and protective effects in ischemia heart.

More Information Supplier Page

Eleutheroside E 10mg  | ≥98%

CSNpharm

Eleutheroside E, a principal component of Eleutherococcus enticosus, has anti-inflammatory and protective effects in ischemia heart.

More Information Supplier Page

Eliprodil 5mg  | ≥99%

CSNpharm

Eliprodil can antogonize GluN2B-selective NMDA in a non-competitive manner with IC50 value of 1 μM. It is also a σ1 ligand with Ki value of 0.013 μM.

More Information Supplier Page

Eliprodil 10mg  | ≥99%

CSNpharm

Eliprodil can antogonize GluN2B-selective NMDA in a non-competitive manner with IC50 value of 1 μM. It is also a σ1 ligand with Ki value of 0.013 μM.

More Information Supplier Page

Eliprodil 25mg  | ≥99%

CSNpharm

Eliprodil can antogonize GluN2B-selective NMDA in a non-competitive manner with IC50 value of 1 μM. It is also a σ1 ligand with Ki value of 0.013 μM.

More Information Supplier Page

Eliprodil 50mg  | ≥99%

CSNpharm

Eliprodil can antogonize GluN2B-selective NMDA in a non-competitive manner with IC50 value of 1 μM. It is also a σ1 ligand with Ki value of 0.013 μM.

More Information Supplier Page

Ellagic Acid 250mg  | ≥99%

CSNpharm

Ellagic acid is a potent and cell permeable casein kinase 2 (CK2) inhibitor with Ki of 20 nM, acts as a potent antioxidant and anti-mutagenic.

More Information Supplier Page

Ellagic Acid 1g  | ≥99%

CSNpharm

Ellagic acid is a potent and cell permeable casein kinase 2 (CK2) inhibitor with Ki of 20 nM, acts as a potent antioxidant and anti-mutagenic.

More Information Supplier Page

Ellipticine 1mg  | ≥98%

CSNpharm

Ellipticine is a potent antineoplastic agent exhibiting multiple mechanisms of action, IC50 of 1.25±0.13, 0.67±0.06, 1.25±0.13, 0.67±0.06, 0.27±0.02, 0.44±0.03, 0.49±0.04, and 1.48±0.62 μM for Breast adenocarcinoma MCF-7, Leukemia HL-60, Breast adenocarcinoma MCF-7, Leukemia HL-60, Neuroblastoma IMR-32, Neuroblastoma UKF-NB-3, Neuroblastoma UKF-NB-4, and Glioblastoma U87MG cell, respectively.

More Information Supplier Page

Ellipticine 10mg  | ≥98%

CSNpharm

Ellipticine is a potent antineoplastic agent exhibiting multiple mechanisms of action, IC50 of 1.25±0.13, 0.67±0.06, 1.25±0.13, 0.67±0.06, 0.27±0.02, 0.44±0.03, 0.49±0.04, and 1.48±0.62 μM for Breast adenocarcinoma MCF-7, Leukemia HL-60, Breast adenocarcinoma MCF-7, Leukemia HL-60, Neuroblastoma IMR-32, Neuroblastoma UKF-NB-3, Neuroblastoma UKF-NB-4, and Glioblastoma U87MG cell, respectively.

More Information Supplier Page

Ellipticine 5mg  | ≥98%

CSNpharm

Ellipticine is a potent antineoplastic agent exhibiting multiple mechanisms of action, IC50 of 1.25±0.13, 0.67±0.06, 1.25±0.13, 0.67±0.06, 0.27±0.02, 0.44±0.03, 0.49±0.04, and 1.48±0.62 μM for Breast adenocarcinoma MCF-7, Leukemia HL-60, Breast adenocarcinoma MCF-7, Leukemia HL-60, Neuroblastoma IMR-32, Neuroblastoma UKF-NB-3, Neuroblastoma UKF-NB-4, and Glioblastoma U87MG cell, respectively.

More Information Supplier Page